3rd Gene Therapy for Neurological Disorders

Returning to Boston this December, the 3rd Gene Therapy for Neurological Disorders meeting will welcome discovery, preclinical, translational and clinical industry scientists to share, learn and network for the shared goal of successfully and safely delivering gene therapies to the CNS.

With 40+ expert leaders from the likes of Taysha Gene Therapies, Passage Bio, AskBio, Neurogene, Affinia Therapeutics and Alcyone Therapeutics sharing their progress, don’t miss the chance to join the industry’s definitive physical conference to make new connections and reconnect with your friends and colleagues.

Over 4 comprehensive days of networking, presentations and discussion sessions, this meeting will enable you to:

• Discuss the latest DRG toxicity and immunogenicity research to understand the biology behind AAV toxicity in the CNS
• Evaluate current safety and toxicity strategies to navigate off target effects including redosing options
• Evaluate intraparenchymal, intra-cisterna magna, lumbar intrathecal and systemic delivery routes for CNS indications to assess CNS tropism and biodistribution
• Hear from neurosurgeons at the forefront of delivery and explore the most up to date delivery devices to identify novel innovations and areas for development
• Review pharmacological concepts for preclinical dose selection in NHP biodistribution case studies to optimize dose extrapolation
• Learn about the different vector discovery strategies used to identify vectors with improved CNS tropism and specificity
• Optimize clinical trial design considerations for both paediatric and adult neurological patient populations to showcase efficacy to regulators and deliver value for patients
• Discover the novel indications being targeted by gene therapies such as epilepsy, neuropathic pain and hearing disorders to improve your knowledge of current CNS pipelines

View your copy of the event guide now: https://ter.li/yrofx9